Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422972 | 0.91 | HCRTR2 (0.41) | PDE4BPDE4DHCRTR2GRIN2CMTNR1B | |
| SCHEMBL4423016 | 0.85 | TRPV1 (0.40) | PDE4BPDE4DHCRTR1HCRTR2FKBP1A | |
| SCHEMBL4417027 | 0.81 | MTNR1B (0.47) | ALDH1A1HCRTR1MEN1KMT2AHCRTR2 | |
| SCHEMBL4418264 | 0.81 | MTNR1B (0.52) | HCRTR1MEN1KMT2AHCRTR2GRIN2C | |
| SCHEMBL4421033 | 0.80 | MTNR1B (0.41) | MEN1KMT2AGRIN2CMTNR1BTRPV1 | |
| SCHEMBL4423047 | 0.79 | GRIN2C (0.51) | MEN1KMT2AGRIN2CMTNR1B | |
| SCHEMBL4416192 | 0.78 | GRIN2C (0.47) | MEN1KMT2AGRIN2CMTNR1B | |
| SCHEMBL4413447 | 0.78 | KMT2A (0.55) | PDE4BPDE4DMEN1KMT2AGRIN2C | |
| SCHEMBL4418256 | 0.78 | KMT2A (0.52) | PDE4BPDE4DMEN1KMT2AGRIN2C | |
| SCHEMBL4414434 | 0.78 | PDE4B (0.39) | PDE4BALDH1A1KDM4EHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | PDE4B 1553/4885PDE4D 1906/4885ALDH1A1 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.